Guangyang Yu

1.3k total citations
17 papers, 761 citations indexed

About

Guangyang Yu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Guangyang Yu has authored 17 papers receiving a total of 761 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in Guangyang Yu's work include Ubiquitin and proteasome pathways (4 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer-related molecular mechanisms research (3 papers). Guangyang Yu is often cited by papers focused on Ubiquitin and proteasome pathways (4 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer-related molecular mechanisms research (3 papers). Guangyang Yu collaborates with scholars based in China, United States and India. Guangyang Yu's co-authors include Lijun Jia, Lun–Xiu Qin, Qiongzhu Dong, Ming Lü, Hu‐Liang Jia, Jinhong Chen, Yiwei Chu, Wenwei Zhu, Lian-Xin Wang and Lak Shin Jeong and has published in prestigious journals such as Cell Metabolism, Cancer Research and Molecular & Cellular Proteomics.

In The Last Decade

Guangyang Yu

17 papers receiving 759 citations

Peers

Guangyang Yu

ONCOL

EPIDE

PRM

Gloria Manzotti Italy

Xianqiu Wu China

Adam M. LaBaff United States

Yangfan Lv China

So Mee Kwon South Korea

Karthik Sekar Singapore

Tania Valencia United States

Raphaël Leblanc France

Junwei Song China

Gloria Manzotti Italy

Guangyang Yu

612 ×1.1

255 ×1.0

221 ×1.0

ONCOL

162 ×1.5

EPIDE

124 ×1.4

PRM

Citations per year, relative to Guangyang Yu Guangyang Yu (= 1×) peers Gloria Manzotti

Countries citing papers authored by Guangyang Yu

Since Specialization

Citations

This map shows the geographic impact of Guangyang Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guangyang Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guangyang Yu more than expected).

Fields of papers citing papers by Guangyang Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guangyang Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guangyang Yu. The network helps show where Guangyang Yu may publish in the future.

Co-authorship network of co-authors of Guangyang Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Guangyang Yu. A scholar is included among the top collaborators of Guangyang Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guangyang Yu. Guangyang Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Xu, Yi, et al.. (2025). Interplay between Nrf2 and ROS in regulating epithelial-mesenchymal transition: implications for cancer metastasis and therapy. Molecular Biology Reports. 52(1). 628–628. 1 indexed citations

Zuo, Ling, Jia Ge, Rui Chen, et al.. (2025). The Nrf2-HMOX1 pathway as a therapeutic target for reversing cisplatin resistance in non-small cell lung cancer via inhibiting ferroptosis. Cell Death Discovery. 11(1). 287–287. 2 indexed citations

Wang, Zhanyu, Xinjie Zhou, Guangyang Yu, et al.. (2023). Surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy of rectal adenocarcinoma with penile metastasis: a case report. Journal of Gastrointestinal Oncology. 14(2). 1155–1165. 1 indexed citations

Pang, Ying, et al.. (2021). Tumor mutational burden and immunotherapy in gliomas. Trends in cancer. 7(12). 1054–1058. 29 indexed citations

Yu, Guangyang, Ying Pang, Chimene Kesserwan, et al.. (2021). Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. Cancers. 13(23). 6092–6092. 22 indexed citations

Pang, Ying, Madison Butler, Olga Kim, et al.. (2021). Targeting CDK9 for the Treatment of Glioblastoma. Cancers. 13(12). 3039–3039. 16 indexed citations

Su, Yuting, Madison Butler, Meili Zhang, et al.. (2020). MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment. Neuro-Oncology Advances. 2(1). vdaa065–vdaa065. 24 indexed citations

Lü, Ming, Wenwei Zhu, Xuan Wang, et al.. (2019). ACOT12-Dependent Alteration of Acetyl-CoA Drives Hepatocellular Carcinoma Metastasis by Epigenetic Induction of Epithelial-Mesenchymal Transition. Cell Metabolism. 29(4). 886–900.e5. 101 indexed citations

Lü, Ming, Lu Lu, Qiongzhu Dong, et al.. (2018). Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition. Acta Biochimica et Biophysica Sinica. 50(4). 370–380. 98 indexed citations

10.

Zhou, Jianlin, Shuang Deng, Hongsong Fang, Guangyang Yu, & Hao Peng. (2018). Hsa-let-7g promotes osteosarcoma by reducing HOXB1 to activate NF-kB pathway. Biomedicine & Pharmacotherapy. 109. 2335–2341. 20 indexed citations

11.

Yu, Guangyang, et al.. (2018). Long non-coding RNA ANRIL is associated with a poor prognosis of osteosarcoma and promotes tumorigenesis via PI3K/Akt pathway. Journal of bone oncology. 11. 51–55. 31 indexed citations

12.

Yu, Guangyang, Xuan Wang, Su-Su Zheng, et al.. (2018). RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis. Cellular Physiology and Biochemistry. 47(3). 1152–1166. 26 indexed citations

13.

Zhao, Di, et al.. (2018). A Novel Beam-Steering Method for Spaceborne Interferometric Synthetic Aperture Radar Altimeter. 2010. 1–4. 1 indexed citations

14.

Hua, Wei, Chunjie Li, Zixiao Yang, et al.. (2015). Suppression of glioblastoma by targeting the overactivated protein neddylation pathway. Neuro-Oncology. 17(10). 1333–1343. 74 indexed citations

15.

Xu, Junfeng, Lihui Li, Guangyang Yu, et al.. (2014). The Neddylation-Cullin 2-RBX1 E3 Ligase Axis Targets Tumor Suppressor RhoB for Degradation in Liver Cancer. Molecular & Cellular Proteomics. 14(3). 499–509. 46 indexed citations

16.

Gao, Qiang, Guangyang Yu, Jie-Yi Shi, et al.. (2014). Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target. Oncotarget. 5(17). 7820–7832. 67 indexed citations

17.

Luo, Zhongguang, Guangyang Yu, Hyuk Woo Lee, et al.. (2012). The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth. Cancer Research. 72(13). 3360–3371. 202 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact